Compare Capital One Financial Corp. (COF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? Capital One Financial Corp. trades at $223.86 (market cap $136.46B), while State Street SPDR S&P Biotech ETF trades at $159.86. The key difference: Capital One Financial Corp. pays a 1.44% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Capital One Financial Corp. nearer its low. Which is the better fit depends on your goals.
| COF | XBI | |
|---|---|---|
Market Cap | $136.46B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $257.94 | $164.28 |
52-Week Low | $176.10 | $88.79 |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $223.09, up 1.88% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.07 and P/B of 1.18, while Q2 2026 earnings beat expectations. Recent news highlights the Discover integration progress and a 20-year arena naming rights extension, reinforcing brand commitment.
The outlook is positive with a consensus price target of $251.60, implying 13% upside, supported by 63% analyst buy ratings. Key risks include integration execution of Discover, credit loss provisions, and macroeconomic sensitivity. Revenue growth to $62.0B in 2026 projects a net income margin rebound to 16.96%, offering a compelling value proposition if synergies materialize.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
